Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vociprotafib · RMC-4630, SAR442720

Small molecule · Inhibitor of SHP2 (protein tyrosine phosphatase non-receptor type 11) (PTPN11) · developed by Revolution Medicines

Phase 2 Most advanced trial (none active)
RVMD Developer
2 Registered trials

What is Vociprotafib?

Vociprotafib is an orally bioavailable inhibitor of SHP2, a protein tyrosine phosphatase encoded by PTPN11. By inhibiting SHP2 it blocks SHP2-mediated signaling through the RAS-RAF-MEK-ERK (MAPK) pathway, which is studied in non-small cell lung cancer and metastatic neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RMC-4630, SAR442720, RMC-0694630
Drug type
Small molecule
Targets
SHP2 (protein tyrosine phosphatase non-receptor type 11) (PTPN11)
Mechanism
Inhibitor of SHP2 (protein tyrosine phosphatase non-receptor type 11) (PTPN11)
Pathways
RAS-RAF-MEK-ERK (MAPK) signaling, PD-1 signal transduction
Therapy area
Oncology
Developer
Revolution Medicines, Inc. (RVMD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
C4YBF9170L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05054725 Phase 2 Non-Small Cell Lung Cancer Completed RVMD
NCT04418661 Phase 1/2 Metastatic Neoplasm Terminated RVMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic NeoplasmNon-Small Cell Lung Cancer

Other drugs acting on PTPN11

More from Revolution Medicines

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RVMD page.

Follow RVMD, the company behind Vociprotafib

See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RVMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.